LAMF Global Ventures Corp. I (Nasdaq: LGVC) announced this morning that it has signed a non-binding letter of intent (LOI) to combine with a leading FDA-cleared innovator in pregnancy care, Nuvo Group Ltd.
Under the LOI, LAMF contemplates Nuvo at a pre-money equity valuation of $269 million, excluding a seller earnout of approximately $31 million. Jeffrey Soros and affiliates of 10X Capital have committed to make a financial investment in Nuvo in connection with the entry into a definitive agreement.
The SPAC has not disclosed further details on the transaction just yet, but expects to provide more information when a definitive agreement is executed. Once the agreements are finalized, the business combination is expected to close during the second half of 2023. The parties also intend to list the combined company on the Nasdaq under the ticker “NUVO”. It is expected to be led by Nuvo’s current CEO, Kelly Londy.
Nuvo has developed INVU, an FDA-cleared, prescription-initiated, remote pregnancy monitoring platform that enables the delivery of remote NSTs (Non-Stress Tests) and maternal & fetal heart rate monitoring, helping expectant parents adhere to their prescribed care plan.
Additionally, Nuvo has signed U.S.-based relationship agreements with Penn Medicine, Axia Womens’ Health, Banner Health, Ouma, Babyscripts, and others, enabling it to address the market opportunity in the U.S. with a multi-channel commercial strategy. The company is currently expanding its network of university hospital partners that are gateways to international commercialization, including signed agreements with Charite University Hospital in Europe, and Sheba Medical Center in Israel.
LAMF originally announced the pricing of its upsized $220 million IPO in November 2021 and set out to combine with a company that is growth-oriented and prioritizes its relationship directly with consumers in the dynamic world of media, entertainment, sports, e-commerce and technology.
The SPAC currently has a completion deadline of May 16, but is holding a shareholder meeting on May 11 to vote on a proposal to extend its deadline to November 16.
Horizon Space II (NASDAQ:HSPT) has signed a definitive agreement to combine with clinical stage biotech firm SL Bio Ltd. for $5.57 billion in equity consideration. Taipei, Taiwan-based SL Bio is developing drug candidates to treat several cancer types while also selling over-the-counter beauty products derived from natural extracts. The combined company is expected to trade...
At the SPAC of Dawn This is set to be a slower week for votes with just two SPACs seeking an extension and none yet scheduling a meeting for approving a business combination. Integrated Rail & Resources (OTC:IRRX) primed the pump somewhat for investors ahead of its Tuesday special meeting by announcing it has entered...
Terms Tracker for the Week Ending May 9, 2025 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. After the sprint that was last week, with nine IPOs and six new SPAC filings, this week took a breather. Only two SPACs priced, there...
Lake Superior (NASDAQ:LKSPU) has filed for a $100 million SPAC as its CEO attempts to go three-for-three with SPACs that led to completed deals. This new vehicle has one right to a 1/6 share in each unit and some common features of a SPAC underwritten by Cohen & Company in this current climate. Although the...
At the SPAC of Dawn De-SPACs were among the biggest movers in yesterday’s stock market rally, but most of this momentum came on the backs of direct earnings performance. Only three US-listed companies had bigger one-day gains than quantum computing firm D-Wave’s (NYSE:QBTS) +51.2% jump. This came as the company announced $15 million in revenue...